Review of fexofenadine in the treatment of chronic idiopathic urticaria.

摘要: Chronic idiopathic urticaria (CIU), characterized by the appearance of itchy wheals unknown etiology, can be extremely debilitating and significantly reduce a patient's quality life (QOL). Fexofenadine, non-sedating, H1-receptor selective, long-acting antihistamine, is licensed worldwide for treatment CIU. A number dose-ranging studies have evaluated efficacy safety fexofenadine In two similar North American studies, patients received either HCI (20, 60, 120, or 240 mg bid) placebo. All four doses fexofendine were statistically superior to placebo at reducing pruritus (P < = 0.0238). dose-finding study undertaken in Japanese confirmed that (60 120 an effective dose response was shown all three when results compared. Furthermore, health outcome analyses indicated 60 bid improved QOL. these had consistently comparable profile placebo, with no dose-related trends incidence adverse events. conclusion, well-tolerated CIU, wide therapeutic window. Importantly, lack ethnic differences between from America Asia indicate demonstrated are cross-culturally applicable.